Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I study.

iScience · 2025 · PMC12164209 · PMID 40520088

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Pharmacokinetics The mean serum concentration of BAT6026 in patients with single and multiple doses showed an increasing trend with dose increase ( Figure 2 ).

also in 63,971 other papers

a slight trendno p-value reported

To be noted, a slight trend of declined target lesion reduction with an increasing of dosage was observed in this study.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.